skip to Main Content

News and press

3C Patch® will be the new name for LeucoPatch® in 2019

Based on the positive clinical results documented in the outcome data (recently published in The Lancet Diabetes & Endocrinology) of a major international randomized controlled…

Read more

PRESS RELEASE: New help on the way for people with diabetic foot ulcers

A major international randomized controlled trial (RCT) has just been published in the internationally recognized journal The Lancet Diabetes & Endocrinology and documents the effect…

Read more

PRESS RELEASE: Positive outcome data of large Randomized Controlled Trial presented at American Diabetes Association Scientific Sessions & Reapplix business update

Reapplix business update: • Application of Reapplix’s LeucoPatch® results in significantly higher incidence of healing • Business update: • Established Reapplix Inc in the US…

Read more

Dr. Magnus Löndahl presented Clinical experiences with LeucoPatch and the status of the large RCT at the Innovations in Wound Healing meeting.

MD, PhD Magnus Löndahl one of 4 principal investigators of the large randomized controlled trial of LeucoPatch/3C Patch on diabetic foot ulcers presented “Clinical experiences…

Read more

Reapplix scientific team presented data at The Diabetic Lower Extremity Symposium

Data were presented in a poster format and was titled: “3C Patch derived autologous immune cells delivers immune responses appropriate for the treatment of Diabetic…

Read more

Reapplix presents poster at Diabetic Foot Study Group meeting in Porto

The Reapplix team have the pleasure to participate at the 14TH ANNUAL MEETING OF THE DFSG, 8-10 September 2017. A poster on the “Immunological perspectives…

Read more

PRESS RELEASE: Reapplix announces new US FDA 510(k) clearance for expanded system, including automated centrifuge, a further advancement of its regenerative wound care technology

Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System® including the 3C Patch Centrifuge, currently being used at…

Read more

PRESS RELEASE: New clinical trial to evaluate LeucoPatch® in the treatment of malleoli ulcers

Reapplix today announced that it is funding a new clinical study for LeucoPatch®, on the healing of ulcers on the malleoli, a bony prominence on…

Read more

PRESS RELEASE: Reapplix confirms new funds raised

Press release Reapplix confirms new funds raised Birkerød, Denmark, September 27th, 2016 Reapplix today announced that it has successfully closed a new funding round of…

Read more

PRESS RELEASE: LeucoPatch® Trial to continue following Interim Analysis

Reapplix today announced that it has been informed by the Trial Steering Committee for the ongoing LeucoPatch® Randomized Controlled Trial (ClinicalTrials.gov NCT02224742) that a planned…

Read more

PRESS RELEASE: Reapplix receives US FDA 510(k) clearance

Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System™. Reapplix’s proprietary simple-to-use device technology has been cleared for…

Read more

New paper published studying the impact of LeucoPatch in chronic wounds

A new paper has been published in Clinical & Experimental Immunology. As each LeucoPatch contains a substantial number of leucocytes, the aim of the study…

Read more

Key patents granted in Europe and Eurasia

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in…

Read more

Patent news – Patent granted in Japan

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that a key patent has been granted…

Read more

Patent news – Patents granted in China and Canada

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification of key patent grants in China and…

Read more

Study Shows Effectiveness of LeucoPatch in Healing Diabetic Foot Ulcers

A newly published study using LeucoPatch, a unique active wound therapy, developed by Reapplix ApS (Reapplix), has been published showing that LeucoPatch was highly effective…

Read more

Reapplix Patents Granted in USA and Japan

Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in…

Read more

REAPPLIX ANNOUNCED AS INNOVATION PRIZE WINNER 2014 IN ‘THE ENGINEER’

Reapplix was today announced as the winner of ‘The Engineer’ Product Prize 2014 in the Innovation category. The Engineer’s Product Prize is a prestigious award…

Read more

REAPPLIX – 2014 EY ENTREPRENEUR OF THE YEAR FINALIST

Reapplix was chosen from the selected participants in the 2014 EY Entrepreneur Of The Year in Denmark as a top 3 finalist in the Life…

Read more

PRESS RELEASE: CMS approves Reapplix clinical study for reimbursement coverage

Reapplix ApS (Reapplix), developers of the unique LeucoPatch® active wound therapy, have today announced that the Centers for Medicare and Medicaid Services (CMS) in the…

Read more

PRESS RELEASE: Reapplix announces appointment of Graeme Brookes as new CEO

Reapplix ApS (Reapplix), developers of the unique LeucoPatch active wound therapy, have appointed Graeme Brookes as Chief Executive Officer. Graeme’s appointment significantly strengthens the commercial…

Read more

LeucoPatch support the work of the diabetic foot study group

To support the important work done by the Diabetic Foot Study Group (DFSG), Reapplix - the company behind The LeucoPatch - is a Silver sponsor…

Read more

LeucoPatch featured in Danish television

“Lise Tarnow, TV2 Lorry”: http://www.tv2lorry.dk/arkiv/2014/7/14?video_id=93064

Read more

The large randomized clinical trial of LeucoPatch speeds up

Clinical sites are continuously being added to the LeucoPatch RCT Recently sites in Lincoln, Dudley and Sheffield have joined us - welcome!

Read more

Large international randomized controlled trial on LeucoPatch started 2013

A study of more than 250 diabetic foot ulcer patients will be initiated in cooperation with principal investigators Dr. Löndahl, Dr. Game, Prof. Jeffcoate and…

Read more

Scandinavian multicenter study of LeucoPatch presentented at EWMA 2013

Final clinical data from the LeucoPatch diabetic foot ulcer study were presented by Clinical investigator Dr. Bo Jørgensen at the European Wound Management Association meeting…

Read more
Back To Top
X